Elsevier

Brain Research

Volume 667, Issue 1, 19 December 1994, Pages 129-132
Brain Research

Intracerebroventricular treatment with an antisense oligodeoxynucleotide to κ-opioid receptors inhibited κ-agonist-induced analgesia in rats

https://doi.org/10.1016/0006-8993(94)91723-XGet rights and content

Abstract

In vivo treatment with an antisense (AS) phosphorothioate oligodeoxynucleotide (oligo) to the rat κ-opioid receptor selectively inhibited κ-mediated analgesia in the rat cold-water tail-flick test. Intracerebroventricular (i.c.v.) AS oligo significantly inhibited the analgesic effect of i.c.v. spiradoline, but not that of μ- or δ-opioid agonists. The dose-effect curve for s.c. spiradoline was shifted to the right after AS, but not missense or sense oligo treatment. Thus, AS oligos provide another technique with which to selectively manipulate opioid receptors and further support the role of non-μ opioid receptors in mediating analgesia in rats.

Reference (33)

  • WahlestedtC.

    Antisense oligunucleotide strategies in neuropharmacology

    Trends Pharmacol. Sci.

    (1994)
  • ZhangM. et al.

    Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates

    Neurosci. Lett.

    (1993)
  • AdamsJ.U. et al.

    Isobolographic superadditivity between delta and mu opioid agonists in the rat depends on the ratio of compounds, the mu agonist and the analgesic assay used

    J. Pharmacol. Exp. Ther.

    (1993)
  • ChenY. et al.

    Molecular cloning and functional expression of a μ-opioid receptor from rat brain

    Mol. Pharmacol.

    (1993)
  • ChenY. et al.

    Molecular cloning of a rat κ-opioid receptor reveals sequence similarities to the μ and δ opioid receptors

    Biochem. J.

    (1993)
  • EvansC.J. et al.

    Cloning of a delta opioid receptor by functional expression

    Science

    (1992)
  • Cited by (45)

    • An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice

      2006, Neuroscience
      Citation Excerpt :

      Two i.c.v. infusions of MOR AS ODN produced no change in baseline behavior compared with either i.c.v. saline or mismatch ODN control. Although the magnitude of MOR knockdown following two AS infusions is unknown, several studies using AS ODNs have shown that the analgesic effects of opioids are markedly reduced following as few as three intermittent AS ODN infusions (Adams et al., 1994; Zhou et al., 1994; Chen et al., 1995). The present findings of unchanged baseline data complement previous findings from our laboratory using the nonselective opioid receptor antagonist naltrexone in an administration paradigm that continuously blocked MORs in wild-type C57BL/6J mice (Hummel et al., 2004a) and an investigation using MOR knockout mice performed by Hall et al. (2004), but contradict findings in MOR-1 C57BL/6J knockouts (Hummel et al., 2004a).

    • Placenta ingestion by rats enhances δ- and κ-opioid antinociception, but suppresses μ-opioid antinociception

      2004, Brain Research
      Citation Excerpt :

      Furthermore, the κ-receptor-specific nature of spiradoline antinociception can be asserted on the basis of its reversibility by κ-selective antagonism. This has been demonstrated both with conventional pharmacological strategies and with molecular (antisense) techniques [4,8,60]. These results indicate that the antinociceptive effects of spiradoline are mediated exclusively at the κ receptor, and together with evidence that POEF decreases the μ antinociception generated by DAMGO (Experiment 2), make it very likely that the enhancing action of POEF on antinociception induced by the low dose of spiradoline represents a κ, and not a μ, effect.

    • Chapter I Opioid receptors

      2002, Handbook of Chemical Neuroanatomy
    • The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system

      2002, Pharmacology and Therapeutics
      Citation Excerpt :

      The latest molecular advances implicating opioid receptor modulation of blood pressure make use of antisense oligodeoxynucleotide (ODN) technology. Antisense ODNs are small DNA fragments that are constructed to be complementary to a defined nucleotide sequence of a specific mRNA (Matteucci & Wagner, 1996; Adams et al., 1994; Chien, C. C. et al., 1994). Recently, these molecular agents have been used to investigate the involvement of opioids in blood pressure regulation.

    View all citing articles on Scopus

    This work was supported by Grants T32 DA07237, DA00376 and DA04745 from the National Institute on Drug Abuse.

    View full text